Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of asthma for a period of at least 6 months prior to Visit 1 with current asthma severity ≥ step 4 (GINA 2017).~* Patients who had used ICS/LABA combinations for asthma for at least 3 months and at stable medium or high dose of ICS/LABA for at least 1 month prior to Visit 1.~* Patients were required to be symptomatic at screening despite treatment with medium or high stable doses of ICS/LABA as defined by ACQ-7 score ≥ 1.5 at visits 101 and 201 (randomization visit).~* Patients with history of at least one severe asthma exacerbation which required medical care from a physician, emergency room visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1 and required systemic corticosteroid treatment for at least 3 days including physician guided self-management treatment with oral corticosteroids as part of written asthma action plan.~* Pre-bronchodilator FEV1 of \< 85 % of the predicted normal value for the patient after withholding bronchodilators prior to spirometry at both Visit 101 and Visit 201.~* Patients who demonstrated an increase in FEV1 of ≥ 12% and 200 ml.~Exclusion Criteria:~* Patients who had a smoking history of greater than 20 pack years.~* Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).~* Patients who had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening).~* Patients treated with a LAMA for asthma within 3 months prior to Visit 1.~* Patients who had a respiratory tract infection or clinical significant asthma worsening as defined by Investigator within 4 weeks prior to Visit 1 or between Visit 1 and Visit 201.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVM149 150/50/80 μg (Type: EXPERIMENTAL): QVM149 150/50/80 μg o.d. delivered via Concept1
- QVM149 150/50/160 μg (Type: EXPERIMENTAL): QVM149 150/50/160 μg o.d. delivered via Concept1
- Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg (Type: ACTIVE_COMPARATOR): Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®

Based on this trial design, predict the completion outcome and termination type (if applicable).